London open: Astra leads advance
29th Jul 2010 08:49
London's blue chips are cautiously higher in early dealings on Thursday as investors consider a bunch of corporate figures. AstraZeneca is the best performer in early dealings. The group's potential blockbuster heart drug Brilinta has received the backing of a US advisory panel just as the drug gia
Read moreUK MARKET TALK ROUNDUP: SHARES GAINING
29th Jul 2010 08:03
Stocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 0703 GMT [Dow Jones] AstraZeneca (AZN.LN) earnings are a strong set, with FY core EPS guidance raised to $6.35-$6.65 from
Read moreMARKET TALK: AstraZeneca Numbers Strong;FY EPS Guidance Raised
29th Jul 2010 08:03
0703 GMT [Dow Jones] AstraZeneca (AZN.LN) earnings are a strong set, with FY core EPS guidance raised to $6.35-$6.65 from $6.05-$6.35, says Shore Capital. Adds the company has also increased its share buyback in 2010 to $2B from $1B, "catalysed we believe by a combination of the positive outcome of
Read moreAstraZeneca gets Brilinta boost, ups guidance
29th Jul 2010 07:48
AstraZeneca's potential blockbuster heart drug Brilinta has received the backing of a US advisory panel just as the drug giant increased 2010 earnings targets for a second time this year following a strong performance from emerging markets and key drugs in the second quarter. The US Food and Drug
Read moreMARKET TALK: AstraZeneca's Drug FDA Backing Seen Consistent
29th Jul 2010 07:37
0637 GMT [Dow Jones] AstraZeneca's (AZN.LN) backing by US FDA panel for the use of Brilinta, a proposed anti-clotting drug, was consistent with expectations, says UBS, though contrasted with "market concerns of a split panel, a narrow label, and/or requirements for more trials before US approval." A
Read moreUK MARKET TALK ROUNDUP: BROKERS COMMENTS
29th Jul 2010 07:37
Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 0637 GMT [Dow Jones] AstraZeneca's (AZN.LN) backing by US FDA panel for the use of Brilinta, a proposed anti-clotting drug, w
Read morePRESS RELEASE: FDA Advisory Committee Recommends US FDA Approval of Brilinta (Ticagrelor) for Acute Coronary Syndromes
28th Jul 2010 23:50
WILMINGTON, Del., July 28 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZeneca's investigational drug ticagrelor for the reduction of thrombotic event
Read moreUPDATE: FDA Panel Backs Use Of AstraZeneca Anticlotting Drug Brilinta
28th Jul 2010 22:34
(Updates with FDA decision deadline, company comments.) By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--A U.S. Food and Drug Administration panel Wednesday backed the use of ticagrelor, a proposed anticlotting drug developed by AstraZeneca PLC (AZN, AZN.LN), de
Read moreFDA Panel Backs Use Of AstraZeneca Anticlotting Drug Brilinta
28th Jul 2010 21:51
By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--A Food and Drug Administration panel Wednesday backed the use of ticagrelor, a proposed anticlotting drug developed by AstraZeneca PLC (AZN, AZN.LN), despite concerns the product might not work in U.S. patients. T
Read moreThursday preview: Shell, Astra, BSkyB ...
28th Jul 2010 16:54
Anglo-Dutch titan Royal Dutch Shell is the last of the major integrated oil companies to report in the current results season. Until the recent Gulf of Mexico oil spill debacle it had been languishing somewhat in the shadow of long time rival BP but the travails of its beleaguered rival has taken s
Read moreOn Dow Jones Investment Banker Today: Genzyme, Kirin, Booz Allen
27th Jul 2010 20:08
LONDON (Dow Jones Investment Banker)--The following columns have been published exclusively on Dow Jones Investment Banker in recent days. Many Dow Jones Investment Banker columns contain spreadsheets, video, PDFs and other supporting material. To arrange access to the best of Dow Jones news and opi
Read moreTIP SHEET: Live Oak Health Fund Finds Value In Neglected Areas
27th Jul 2010 12:35
(This article was originally published Monday.) By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Mark Oelschlager treads a different path in running the Live Oak Health Sciences Fund (LOGSX). Unlike some health-care fund managers, he didn't come from a career in the pharm
Read moreUK MARKET TALK ROUNDUP: SHARES GAINING
27th Jul 2010 11:34
Stocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 1034 GMT [Dow Jones] Panmure Gordon & Co analyst Savvas Neophytou says AstraZeneca PLC's (AZN) shares to rise Tuesday on U
Read moreMARKET TALK: AstraZeneca Boost Seen On Brilinta Hopes
27th Jul 2010 11:34
1034 GMT [Dow Jones] Panmure Gordon & Co analyst Savvas Neophytou says AstraZeneca PLC's (AZN) shares to rise Tuesday on U.S. Food and Drug Administration documents, released ahead of a Wednesday advisory panel, which raises hopes for its experimental blood thinner Brilinta. "Our reading of the key
Read moreFDA Questions Effectivness Of AstraZeneca Anticlotting Drug
26th Jul 2010 20:55
By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--The Food and Drug Administration questioned the effectiveness of ticagrelor, a proposed anticlotting drug developed by AstraZeneca PLC (AZN, AZN.LN). The company is seeking FDA approval of the product to prevent hea
Read more